SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2019 / Cilt: 44 - Sayı: 6

Simultaneous comparison of L-NAME and melatonin effects on RAW 264.7 cell line’s iNOS production and activity

Behrooz JOHARİ
Masoumeh AZİZİ
Mohammad MORADİ
Mohammad Hessam RAFİEE
Pages
840–847
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Dose-dependent activity of iNOS in LPS-induced cellsfrom non-treated to 4 mM L-NAME showed 79% reduction while at the same concentrations of melatonin thisdecrease was 32% (p-value

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: NO (nitric oxide) inhibition could be used forevaluating the drug’s efficacy for NO-mediated inflammatory disorders.
📊
Key Findings & Data:The aim of this study was to investigate theinfluence of L-NAME and melatonin on different NO production levels in RAW 264.7 cell line as an in vitro modelfor inflammatory diseases.Materials and methods: RAW 264.7 macrophage cell linewas used to compare the effects of L-NAME and melatoninon basal and Lipopolysaccharide (LPS)-induced iNOSlevels.
💡
Conclusion & Impact:Dose-dependent activity of iNOS in LPS-induced cellsfrom non-treated to 4 mM L-NAME showed 79% reduction while at the same concentrations of melatonin thisdecrease was 32% (p-value
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: NO (nitric oxide) inhibition could be used forevaluating the drug’s efficacy for NO-mediated inflammatory disorders. The aim of this study was to investigate theinfluence of L-NAME and melatonin on different NO production levels in RAW 264.7 cell line as an in vitro modelfor inflammatory diseases.Materials and methods: RAW 264.7 macrophage cell linewas used to compare the effects of L-NAME and melatoninon basal and Lipopolysaccharide (LPS)-induced iNOSlevels. The cells were treated using L-NAME and melatonin for 1 h, afterward incubated with/without LPS for 8and 24 h. Finally, iNOS mRNA, protein, activity, and nitriteconcentrations were evaluated.Results: Inhibition rate of nitrite by 1 mM L-NAME compared with LPS control were 78% and 80% during 8 and24 h, respectively. Real-time PCR showed that in the LPStreated group, 1 mM L-NAME could result in 14% increaseof iNOS-mRNA compared with the control group during8 h. Dose-dependent activity of iNOS in LPS-induced cellsfrom non-treated to 4 mM L-NAME showed 79% reduction while at the same concentrations of melatonin thisdecrease was 32% (p-value

🔖

Cite This Article

JOHARİ, B., AZİZİ, M., MORADİ, M., RAFİEE, M. H. (2022). Simultaneous comparison of L-NAME and melatonin effects on RAW 264.7 cell line’s iNOS production and activity. Türk Biyokimya Dergisi, Cilt: 44 - Sayı: 6, 840–847. https://ajindex.com/articles/620901

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bogdan C. Nitric oxide synthase in innate and adaptive immunity: an update. Trends. Immunol 2015;36:161–78
  2. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323–50
  3. Sarchielli P, Floridi A, Mancini ML, Rossi C, Coppola F, Baldi A, et al. NF-kappaB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks. Cephalalgia 2006;26:1071–9
  4. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factorkappaB as a molecular target for migraine therapy. Ann Neurol 2002;51:507–16
  5. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature’s most versatile biological signal? FEBS J 2006;273:2813–38
  6. Fooladsaz K, Ansari M, Rasaie MJ. Evaluation and comparison of serum melatonin determination in normal individuals and migraine patients. Tehran Univ Med J 2004;62:43–8
  7. Loder E, Harrington MG, Cutrer M, Sandor P, De Vries B. Selected confirmed, probable, and exploratory migraine biomarkers. Headache 2006;46:1108–27
  8. Peres MF, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Invest Drug 2006;15:367–75
  9. Zhang S, Li W, Gao Q, Wei T. Effect of melatonin on the generation of nitric oxide in murine macrophages. Eur J Pharmacol 2004;501:25–30
  10. Hoskin KL, Bulmer DC, Goadsby PJ. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett 1999;266:173–6
  11. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010;9:285–98
  12. Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics 2010;7:183–90
  13. Chen YC, Shen SC, Lee WR, Hou WC, Yang LL, Lee TJ. Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin, and quercetin pentaacetate in RAW 264.7 macrophages. J Cell Biochem 2001;82:537–48
  14. Naureckiene S, Edris W, Ajit SK, Katz AH, Sreekumar K, Rogers KE, et al. Use of a murine cell line for identification of human nitric oxide synthase inhibitors. J Pharmacol Toxicol Metthods 2007;55:303–13
  15. Aviram A, Tsoukias NM, Melnick SJ, Resek AP, Ramachandran C. Inhibition of nitric oxide synthesis in mouse macrophage cells by feverfew sup